ESMO 2019 | CheckMate 227 dual IO therapy: nivo plus ipilimumab upfront for NSCLC
Solange Peters, MD, PhD, of University Hospital Vaudois, Lausanne, Switzerland, presents the CheckMate 227 trial final analysis (NCT02477826) at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain. Importantly, Prof. Peters highlights that nivolumab and low-dose ipilimumabwere well tolerated in non-small cell lung cancer. After the presentation, Marina Garassino, MD, National Cancer Institute of Milan, Milan, Italy, discusses the results and puts them in context.
Get great new content delivered to your inboxSign up